Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$151.22 3.82 (2.59%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 123,030,000
Market Cap: 18.60(B)
Last Volume: 934,860 Avg Vol: 724,527
52 Week Range: $143.31 - $211.65
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  824
Guru Rank Value     : 0.5
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,264 76,855 102,504 247,093
Total Sell Value $6,835,665 $12,957,715 $17,713,340 $48,829,179
Total People Sold 6 7 8 9
Total Sell Transactions 10 12 18 35
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 746
  Page 20 of 30  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Maraganore John CEO   •       •      –    2014-04-14 4 OE $9.14 $524,962 D/D 28,707 106,320     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-03-25 4 B $66.88 $23,036,682 I/I 344,448 9,110,786 1.5     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-03-18 4 AS $73.34 $2,423,223 D/D (32,769) 0     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-03-18 4 OE $7.10 $380,002 D/D 32,769 32,769     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-27 3 IO $0.00 $0 I/I 0 8,766,338     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-02-21 4 D $90.10 $235,611 I/I (2,615) 0     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-02-19 4 AS $78.62 $1,633,240 D/D (20,400) 3,905     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-02-19 4 OE $7.10 $126,965 D/D 13,500 24,305     -
   Maraganore John CEO   •       •      –    2014-02-03 4 OE $6.78 $314,124 D/D 46,331 77,613     -
   Greene Barry E President and COO   •       –      –    2014-02-03 4 D $78.68 $132,182 D/D (1,680) 33,592     -
   Greene Barry E President and COO   •       –      –    2014-02-03 4 OE $6.78 $132,210 D/D 19,500 35,272     -
   Mason Michael VP, Finance and Treasurer   •       –      –    2014-02-03 4 AS $78.08 $294,992 D/D (3,750) 1,537     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-01-24 4 AS $84.57 $676,589 D/D (7,890) 0     -
   Mason Michael VP, Finance and Tresurer   •       –      –    2014-01-23 4 D $89.49 $229,094 D/D (2,560) 5,287     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-01-23 4 D $89.49 $330,934 D/D (3,698) 10,805     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-01-23 4 D $89.49 $420,424 D/D (4,698) 7,890     -
   Schimmel Paul Director   –       •      –    2014-01-13 4 AS $85.36 $1,280,400 D/D (15,000) 0     -
   Schimmel Paul Director   –       •      –    2014-01-13 4 OE $15.82 $237,300 D/D 15,000 15,000     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2013-12-30 4 D $64.51 $59,994 D/D (930) 14,503     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2013-12-30 4 OE $15.99 $59,994 D/D 3,752 15,433     -
   Schimmel Paul Director   –       •      –    2013-12-26 4 GD $0.00 $0 I/I 3,500 310,996     -
   Schimmel Paul Director   –       •      –    2013-12-20 4 AS $65.00 $975,000 D/D (15,000) 0     -
   Schimmel Paul Director   –       •      –    2013-12-20 4 OE $11.33 $169,950 D/D 15,000 15,000     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2013-12-17 4 AS $60.59 $1,127,761 D/D (18,480) 12,588     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2013-12-17 4 OE $12.96 $239,501 D/D 18,480 31,068     -
  746 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 20 of 30
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us